Explore

Companies

Drugs

/

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Oncology/Anatomic Stage III Breast Cancer AJCC V8

Anatomic Stage III Breast Cancer AJCC V8

22

Pipeline Programs↗

10

Active Trials↗

12

Companies Involved↗

Anatomic Stage III Breast Cancer AJCC v8 is an emerging landscape with 22 programs across 12 companies. 4 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

50/100

Pipeline Velocity

6/100

Mech. Concentration

13/100

Completion Rate

0/100

Attrition Rate

0/100

Pipeline

Programs by Phase

Preclinical5

Cyclophosphamide

Baxter Healthcare Corporation

Neoantigen Peptide Vaccine

The First Affiliated Hospital of Nanchang University

Sargramostim

Sanofi

Copanlisib Hydrochloride

National Cancer Institute (NCI)

Eribulin Mesylate

Eisai

Phase 110

Pidnarulex

National Cancer Institute (NCI)

Trastuzumab Deruxtecan

AstraZeneca

Abemaciclib

Eli Lilly

BET Bromodomain Inhibitor ZEN-3694

National Cancer Institute (NCI)

Nab-Paclitaxel

Bristol-Myers Squibb

Phase 23

Atezolizumab

Roche

Olaparib

AstraZeneca

Talazoparib

Pfizer

Phase 34

Entinostat

Syndax Pharmaceuticals

Exemestane

Pfizer

Goserelin

TerSera Therapeutics LLC

Goserelin Acetate

TerSera Therapeutics LLC

Approved

No programs

Analysis

Modality Breakdown

64%

Small molecule

14 of 22 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 22 classified programs, each share of the total. Modality classified for 100% of 22 pipeline programs.

Analysis

Trial Status

11

clinical trials

Active, not recruiting6 · 55%

Recruiting4 · 36%

Suspended1 · 9%

Clinical Trials

Trial Activity

11 trials

A Phase I/II Study of Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab in Advanced Solid Tumors (PNeoVCA)

Recruiting·MMayo Clinic·Preclinical·NCT05269381·138 enrolled

A Phase 1b Trial of ZEN003694 (ZEN-3694) With Pembrolizumab and Nab-Paclitaxel in Patients With Metastatic Triple-Negative Breast Cancer

Recruiting·National Cancer Institute (NCI)·Phase 1·NCT05422794·57 enrolled

A Phase 1 Study of BET Bromodomain Inhibitor ZEN003694 in Combination With the CDK4/6 Inhibitor Abemaciclib in Patients With NUT Carcinoma, Breast Cancer and Other Solid Tumors

Recruiting·National Cancer Institute (NCI)·Phase 1·NCT05372640·45 enrolled

Phase 1b Study of Pidnarulex and Trastuzumab Deruxtecan in Patients With HER2 Expressing Solid Tumors

Recruiting·National Cancer Institute (NCI)·Phase 1·NCT07137416·36 enrolled

A Phase 1 Study Evaluating Safety, Tolerability, and Preliminary Antitumor Activity of Entinostat and Nivolumab With or Without Ipilimumab in Advanced Solid Tumors

Active, not recruiting·National Cancer Institute (NCI)·Phase 1·NCT02453620·57 enrolled

A Phase II Open-Label, Randomized Study of PARP Inhibition (Olaparib) Either Alone or in Combination With Anti-PD-L1 Therapy (Atezolizumab; MPDL3280A) in Homologous DNA Repair (HDR) Deficient, Locally Advanced or Metastatic Non-HER2-Positive Breast Cancer

Active, not recruiting·National Cancer Institute (NCI)·Phase 2·NCT02849496·89 enrolled

Phase IB Trial of Niraparib and Dostarlimab (TSR-042) in Patients With BRCA-Mutated Breast, Pancreas or Ovary Cancer

Active, not recruiting·UUniversity of Washington·Phase 1·NCT04673448·18 enrolled

A Pharmacodynamics-Driven Trial of Talazoparib, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Aberrations in Genes Involved in DNA Damage Response

Active, not recruiting·National Cancer Institute (NCI)·Phase 2·NCT04550494·29 enrolled

A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer

Active, not recruiting·National Cancer Institute (NCI)·Phase 3·NCT02115282·608 enrolled

A Phase I/II Trial Evaluating the Safety and Efficacy of Eribulin in Combination With Copanlisib in Patients With Metastatic Triple Negative Breast Cancer

Active, not recruiting·National Cancer Institute (NCI)·Preclinical·NCT04345913·24 enrolled

Phase I Study Targeting DNA Methyltransferases in Metastatic Triple-Negative Breast Cancer

Suspended·National Cancer Institute (NCI)·Phase 1·NCT05673200·32 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)